Business Wire

NY-HANSHOW

Share
Hanshow Unveils New Generation Protocol and Four-Color ESL at NRF 2023

Hanshow participated in the 2023 National Retail Federation (NRF), the largest retail event in the world. At this year’s NRF Exhibition Booth, Hanshow unveiled a new generation protocol high-density low-power cellular network (HiLPC) and four-color Electronic Shelf Label (ESL). Hanshow has strengthened the operability of both its hardware and software and now provides more advanced solutions and services for the digital upgrading of retail industry customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005732/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hanshow's new generation protocol high-density low-power cellular network (HiLPC) (Graphic: Business Wire)

Rapid upgrading that is more than just “fast”

Hanshow already provided the world’s leading series of ESL products, and this advanced performance has been further improved through Hanshow’s new generation HiLPC. With HiLPC innovative system architecture, the communication speed of the ESL is greatly improved, and the update speed can reach over 60,000 pieces/hour/ESL controller, making it quicker and easier to install and bind. The super-high system throughput of the HiLPC enables updating tens of millions of devices within a few minutes, which brings clients a totally novel experience of real-time ESL services and enhances clients’ capability of managing globally distributed stores.

With this upgraded protocol, Hanshow ESL Solution enables batch, timed, and synchronized task updates in the same store with errors controlled at the millisecond level, and it can also synchronize dynamic price changes, realize precise timing synchronization while online and even offline, and track the position of products, greatly improving the operational efficiency of stores.

The new generation HiLPC makes it possible to nomadically update ESLs, which opens opportunities for new industrial applications. It also supports flashing light prompts for any number of goods being selected to help employees quickly find the location of goods for sorting. It supports dynamic network resource allocation used in conjunction with Wi-Fi, solving the network incompatibility challenges. In addition, the new generation protocol combined with ESL controllers and financial-grade security chips provides the most reliable data protection available.

Breaking through with smarter and better performance

Hanshow also unveiled the four-color ESL product series that supports black, white, red, and yellow color displays in any combination, expanding the digital display possibilities for retailers. This product’s screen updating and flashing speeds are significantly optimized compared with previous models, especially in conjunction with the new generation HiLPC.

In addition to the breakthrough in vivid displays, Hanshow has focused on increasing its precision applications for specific industry demands. Hanshow’s thermal detector and DIY ESL solutions are designed to help retailers solve special applications for temperature monitoring and automatic temperature change alerts, as well as the product use adaptation problems of home improvement retail and other business forms.

For years, Hanshow has pursued continuous innovation based on customer needs and remained committed to enabling customers to achieve upgrading for better operational efficiency. The new generation HiLPC and four-color ESL directly achieve this by drastically reducing the energy supply and paper materials needed to operate a physical store. In the future, Hanshow will continue developing innovative digital technology, fully assist customers in digital upgrading, and create a green, leading, and sustainable digital new experience in the industry.

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005732/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye